A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier
Authors:
- Jens P. BankstahlJBJens P. Bankstahl
- Marion BankstahlMBMarion Bankstahl
- Claudia KuntnerCKClaudia Kuntner
- Johann StanekJSJohann Stanek
- Thomas WanekTWThomas Wanek
- Martin MeierMMMartin Meier
- Xiao-Qi DingXDXiao-Qi Ding
- Markus MüllerMMMarkus Müller
- Oliver LangerOLOliver Langer
- Wolfgang LöscherWLWolfgang Löscher
- 15 June 2011
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 31 (24) , 8803-8811
Abstract
Approximately one-third of epilepsy patients are pharmacoresistant. Overexpression of P-glycoprotein and other multidrug transporters at the blood–brain barrier is thought to play an important role in drug-refractory epilepsy. Thus, quantification of regionally different P-glycoprotein activity in the brain in vivo is essential to identify P-glycoprotein overactivity as the relevant mechanism for drug resistance in an individual patient. Using the radiolabeled P-glycoprotein substrate (R)-[11C]verapamil and different doses of coadministered tariquidar, which is an inhibitor of P-glycoprotein, we evaluated whether small-animal positron emission tomography can quantify regional changes in transporter function in the rat brain at baseline and 48 h after a pilocarpine-induced status epilepticus. P-glycoprotein expression was additionally quantified by immunohistochemistry. To reveal putative seizure-induced changes in blood–brain barrier integrity, we performed gadolinium-enhanced magnetic resonance scans on a 7.0 tesla small-animal scanner. Before P-glycoprotein modulation, brain uptake of (R)-[11C]verapamil was low in all regions investigated in control and post-status epilepticus rats. After administration of 3 mg/kg tariquidar, which inhibits P-glycoprotein only partially, we observed increased regional differentiation in brain activity uptake in post-status epilepticus versus control rats, which diminished after maximal P-glycoprotein inhibition. Regional increases in the efflux rate constant k2, but not in distribution volume VT or influx rate constant K1, correlated significantly with increases in P-glycoprotein expression measured by immunohistochemistry. This imaging protocol proves to be suitable to detect seizure-induced regional changes in P-glycoprotein activity and is readily applicable to humans, with the aim to detect relevant mechanisms of pharmacoresistance in epilepsy in vivo.Keywords
This publication has 51 references indexed in Scilit:
- P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-LoperamideJournal of Nuclear Medicine, 2010
- Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain BarrierJournal of Cerebral Blood Flow & Metabolism, 2009
- A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PETJournal of Nuclear Medicine, 2009
- Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PETEuropean Journal of Clinical Pharmacology, 2009
- PET radiotracers: crossing the blood–brain barrier and surviving metabolismTrends in Pharmacological Sciences, 2009
- Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy HumansJournal of Nuclear Medicine, 2009
- Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-GlycoproteinJournal of Nuclear Medicine, 2009
- P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in MonkeysJournal of Nuclear Medicine, 2008
- Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PETJournal of Nuclear Medicine, 2008